The field of wound healing faces significant challenges, particularly in the treatment of chronic wounds, which often result in prolonged healing times and complications. Recent advancements in 3D printing technology have provided innovative solutions to these challenges, offering tailored and precise approaches to wound care. This review highlights the role of 3D printing in enhancing wound healing, focusing on its application in creating biocompatible scaffolds, custom wound dressings, and drug delivery systems.
View Article and Find Full Text PDFPurpose: Lennox-Gastaut syndrome (LGS), a rare, severe form of childhood-onset epilepsy, is difficult to control. Rufinamide is indicated for adjunctive treatment of seizures associated with LGS in adults and pediatric patients aged ≥1 year. In clinical practice, rufinamide dosing and titration may differ from the trial setting.
View Article and Find Full Text PDFBehcet's disease (BD) is a chronic inflammatory disease affecting blood vessels throughout the body mainly veins and clinically characterized by oro-genital aphthae ,ophthalmologic involvement ,cutaneous lesions ,articular, neurological involvement and less commonly by gastrointestinal manifestations which may have dreadful complications. Here we report a case of 58 year male with gastrointestinal complications of BD and a rapidly worsening course.
View Article and Find Full Text PDFObjective: To obtain information on the acceptable doses of the antiepileptic drug (AED) retigabine (RTG), the maximum tolerated dose (MTD), drug interactions, safety and tolerability, and preliminary evidence of efficacy when administered as adjunctive therapy and as monotherapy.
Materials: Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy. Following baseline assessments, patients entered a dose titration phase of 28 â 56 days.
Purpose: To evaluate efficacy and safety of adjunctive treatment with rufinamide 1600 mg twice daily in subjects aged > or = 16 years with refractory partial seizures.
Methods: This double-blind, placebo-controlled, randomized, parallel-group, multicenter trial included an 8-week baseline phase and a 13-week double-blind phase. Treatment was initiated with rufinamide 400 mg twice daily or placebo; rufinamide was titrated to 1600 mg twice daily.